Abstract:BACKGROUND:Despite recent advances in the treatment of hepatocellular carcinoma (HCC), the chemotherapy efficacy against HCC is still unsatisfactory. The mammalian target of rapamycin (mTOR) has been emerged as an important cancer therapeutic target. However, HCC cells often resistant to rapamycin because of the paradoxical activation of Akt by rapamycin. In this study, we investigated whether bortezomib could enhance the antitumor effects of rapamycin.METHODS:The effects of rapamycin and bortezomib on HCC proliferation, apoptosis, migration, and invasiveness in vitro were assessed by CCK-8 analysis, flow cytometry, Hoechst 33342 staining and transwell assays, respectively. Total and phosphorylated protein levels of Akt were detected by Western blotting. The effects of rapamycin and/or bortezomib on the mRNA expression levels of p53, p27, p21 and Bcl-2 family in HCCLM3 cells were evaluated by RT-PCR. The roles of rapamycin and bortezomib on HCC growth and metastasis in xenograft models were evaluated by tumor volumes and fluorescent signals. The effects of rapamycin and bortezomib on cell proliferation and apoptosis in vivo were test by PCNA and TUNEL staining.RESULTS:Bortezomib synergized with rapamycin to reduce cell growth, induce apoptosis, and inhibit cell mobility in vitro. Further mechanistic studies showed that bortezomib inhibited rapamycin-induced phosphorylated Akt, which in turn enhanced apoptosis of HCC cell lines. The alteration of the mRNA expression of cell cycle inhibitors p53, p27, p21 and apoptosis associated genes Bcl-2, Bax were also involved in the synergistic antitumor effects of rapamycin and bortezomib. P53 inhibitor PFT-α significantly attenuate the effect of rapamycin and bortezomib on cell apoptosis, which indicated that the pro-apoptotic effect of rapamycin and bortezomib may be p53-dependent. Treatment of HCCLM3-R bearing nude mice with rapamycin and bortezomib significantly enhanced tumor growth inhibition (72.4%), comparing with either rapamycin- (54.7%) or bortezomib-treated mice (22.4%). In addition, the lung metastasis was significantly suppressed in mice received the combination treatment (16.6%). The combination treatment of rapamycin and bortezomib significantly inhibited tumor cell proliferation and tumor angiogenesis in vivo.CONCLUSION:The combination of rapamycin with bortezomib could be a novel and promising therapeutic approach to the treatment of HCC.

Berberine Sensitizes Rapamycin-Mediated Human Hepatoma Cell Death in Vitro

Novel Synergistic Antitumor Effects of Rapamycin with Bortezomib on Hepatocellular Carcinoma Cells and Orthotopic Tumor Model

Synergistic effect of mTOR inhibitor rapamycin and fluorouracil in inducing apoptosis and cell senescence in hepatocarcinoma cells.

Rapamycin enhances the anti-tumor effect of gemcitabine in pancreatic cancer cells

Rapamycin Enhances Cetuximab Cytotoxicity by Inhibiting Mtor-Mediated Drug Resistance in Mesenchymal Hepatoma Cells

Combination of Cetuximab and Rapamycin Enhances the Therapeutic Efficacy in Hepatocellular Carcinoma.

Berberine, a natural plant alkaloid, synergistically sensitizes human liver cancer cells to sorafenib.

Combined Effect of Rapamycin and Cisplatin on Survival of Hep-2 Cells in Vitro

Effect of Rapamycin Alone and in Combination with Sorafenib in an Orthotopic Model of Human Hepatocellular Carcinoma.

Rapamycin inhibits B16 melanoma cell viability in vitro and in vivo by inducing autophagy and inhibiting the mTOR/p70‐S6k pathway

Combining the mammalian target of rapamycin inhibitor, rapamycin, with resveratrol has a synergistic effect in multiple myeloma

Synergistic Effect of Targeting Mtor by Rapamycin and Depleting ATP by Inhibition of Glycolysis in Lymphoma and Leukemia Cells

Dichloroacetic acid and rapamycin synergistically inhibit tumor progression

Berberine Enhances Chemosensitivity and Induces Apoptosis Through Dose-orchestrated AMPK Signaling in Breast Cancer.

Combination of melatonin and rapamycin for head and neck cancer therapy: Suppression of AKT/mTOR pathway activation, and activation of mitophagy and apoptosis via mitochondrial function regulation

Berberine Sensitizes Human Hepatoma Cells to Regorafenib via Modulating Expression of Circular RNAs

Rapamycin Enhances the Anti-Tumor Activity of Cabozantinib in Cmet Inhibitor-Resistant Hepatocellular Carcinoma

DNA Methyltransferase Inhibitor and Rapamycin Synergistically Modulate Cell Cycle and Mammalian Target of Rapamycin Signaling Pathway for Human Colorectal Cancer Cells

Antiproliferative and Overadditive Effects of Rapamycin and FTY720 in Pancreatic Cancer Cells in Vitro

Rapamycin and PD98059 Collaborative Inhibit Mammalian Target of Rapamycin Pathway in the Prevention and Treatment of Mouse Colorectal Cancer

[Synergistic Effect of Rapamycin (RPM) and PD98059 on Cell Cycle and Mtor Signal Transduction in Human Colorectal Cancer Cells].